Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Cabazitaxel, sold under the brand name Jevtana, is a semi-synthetic derivative of a natural taxoid. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.[citation needed]
Read the full article on WikipediaCastration resistant metastatic carcinoma of the prostate Clinical criteria: The treatment must be in combination with prednisone or prednisolone, AND The condition must be resistant to treatment with docetaxel; OR Patient must have a documented intolerance necessitating permanent treatment withdrawal or a contraindication to docetaxel, AND The treatment must not be used in combination with a novel hormonal drug, AND Patient must have a WHO performance status of 2 or less, AND Patient must not receive PBS-subsidised cabazitaxel if progressive disease develops while on cabazitaxel.
“Taxanes enhance microtubule stabilization and inhibit cellular mitosis and division. Moreover, taxanes prevent androgen receptor (AR) signaling by binding cellular microtubules and the microtubule-associated motor protein dynein, thus averting AR nuclear translocation.”
Working under the parallel aged-care framework? Aged-care equivalent →